Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment
Authors
Keywords
-
Journal
Translational Research
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-10-30
DOI
10.1016/j.trsl.2023.10.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease
- (2023) Pascale Gluais Dagorn et al. KIDNEY INTERNATIONAL
- Calcium-sensing receptor activator cinacalcet for treatment of cyclic nucleotide-mediated secretory diarrheas
- (2023) Tifany Chu et al. Translational Research
- Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD
- (2022) Bart J. Kramers et al. Clinical Journal of the American Society of Nephrology
- Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease
- (2022) Xiaofang Wang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Lubiprostone is a Non-Selective Activator of cAMP-Gated Ion Channels and Chloride Channel Protein 2 (Clc-2) Has a Minor Role in its Prosecretory Effect in Intestinal Epithelial Cells
- (2022) Apurva A. Oak et al. MOLECULAR PHARMACOLOGY
- A systematic review and meta-analysis of efficacy and safety of Calcimimetic agents in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease
- (2022) Tianbiao Zhou et al. CURRENT PHARMACEUTICAL DESIGN
- Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease
- (2021) Shinya Nakatani et al. Scientific Reports
- Pre‐clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease
- (2021) Annarita Di Mise et al. FASEB JOURNAL
- Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
- (2021) Ioannis Bellos Therapeutics and Clinical Risk Management
- An update on the use of tolvaptan for ADPKD: Consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders (WGIKD), the European Rare Kidney Disease Reference Network (ERKNet) and Polycystic Kidney Disease International (PKD-International)
- (2021) Roman-Ulrich Müller et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Does In Vitro Potency Predict Clinically Efficacious Concentrations?
- (2020) Rasmus Jansson‐Löfmark et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Targeting chloride transport in autosomal dominant polycystic kidney disease
- (2020) François Jouret et al. CELLULAR SIGNALLING
- Vitamin D and Calcimimetics in Cardiovascular Disease
- (2018) Kenneth Lim et al. SEMINARS IN NEPHROLOGY
- Activation of Calcium-Sensing Receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells
- (2018) Annarita Di Mise et al. Scientific Reports
- Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
- (2017) Markus Ketteler et al. KIDNEY INTERNATIONAL
- Autosomal dominant polycystic kidney disease: the changing face of clinical management
- (2015) Albert C M Ong et al. LANCET
- Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease
- (2013) Olivier Devuyst et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Cinacalcet hydrochloride for the treatment of hyperparathyroidism
- (2013) Nicolas Verheyen et al. EXPERT OPINION ON PHARMACOTHERAPY
- Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease
- (2013) V. E. Torres et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Potent, Metabolically Stable Benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR Inhibitors for Polycystic Kidney Disease
- (2011) David S. Snyder et al. JOURNAL OF MEDICINAL CHEMISTRY
- Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis
- (2011) V. Takiar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical Pharmacokinetic and Pharmacodynamic Profile of Cinacalcet Hydrochloride
- (2009) Desmond Padhi et al. CLINICAL PHARMACOKINETICS
- Calcimimetic Inhibits Late-Stage Cyst Growth in ADPKD
- (2009) V. H. Gattone et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Type II Calcimimetics and Polycystic Kidney Disease: Unanswered Questions
- (2009) V. E. Torres JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1
- (2008) Sekiya Shibazaki et al. HUMAN MOLECULAR GENETICS
- Small-Molecule CFTR Inhibitors Slow Cyst Growth in Polycystic Kidney Disease
- (2008) B. Yang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease
- (2008) X. Wang et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Purinergic signaling in the lumen of a normal nephron and in remodeled PKD encapsulated cysts
- (2008) Michael B. Hovater et al. Purinergic Signalling
- Dose translation from animal to human studies revisited
- (2007) Shannon Reagan-Shaw et al. FASEB JOURNAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now